Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis
Led by University of Siena · Updated on 2025-07-10
3500
Participants Needed
112
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
Brief Title
Who Can Participate
AI-Screening
Your Study Journey
Trial Site Locations
Research Team
How is the study designed?
Similar Trials
Frequently Asked Questions
Research Publications
AI-Summary
What this Trial Is About
Researchers are investigating autoinflammatory diseases (AID), which involve recurring inflammatory episodes without infection, cancer, or adaptive immune system problems. This study focuses on both monogenic hereditary periodic syndromes and polygenic or multifactorial AID, including rare conditions like Behçet's disease, Still disease, Schnitzler's disease, PFAPA syndrome, chronic recurrent multifocal osteomyelitis, non-infectious uveitis and scleritis, among others. The goal is to gather detailed data to improve understanding and management of these rare diseases through an international collaboration.
The study uses the AIDA registry, a secure online platform for collecting demographic, genetic, clinical, laboratory, radiologic, and therapeutic information. Data are gathered retrospectively and prospectively during routine clinical visits scheduled every 3-6 months. Eleven registries focus on different AID conditions, enabling comprehensive data collection to identify clinical patterns, treatment impacts, and long-term outcomes over a period of at least 10 years.
Participants provide information during their usual care visits, allowing researchers to track changes in disease activity, organ involvement, inflammatory markers, visual function, pain levels, fatigue, fertility, and socioeconomic factors. The study monitors these outcomes over multiple timepoints up to 120 months. Data privacy is ensured by pseudonymizing patient information. This registry supports multiple clinical studies and aims to enhance knowledge, awareness, and future research on autoinflammatory diseases worldwide.
CONDITIONS
Brief Title
AutoInflammatory Disease Alliance Registry (AIDA)
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
Diagnosed with a monogenic autoinflammatory disease based on clinical features and confirmative genetic testing
Diagnosed with familial Mediterranean fever, Behçet's disease, Still disease, PFAPA syndrome, Schnitzler's disease, or chronic recurrent multifocal osteomyelitis according to established criteria
Diagnosed with undifferentiated systemic autoinflammatory disease
Diagnosed with non-infectious uveitis following standard nomenclature criteria
Diagnosed with anterior or posterior non-infectious scleritis
Diagnosed with spondyloarthritis according to ASAS and/or New York criteria
Diagnosed with Castleman disease
You will not qualify if you...
Informed consent or assent not provided by the patient or their legal representative
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person or remote)
Long-term Monitoring
Duration - Up to 10 years
Participants diagnosed with autoinflammatory diseases are observed over time with data collected during routine clinical visits.
Routine visits every 3 to 6 months
Trial Site Locations
Total: 112 locations
1
University Algiers 1
Algiers, Algeria
Actively Recruiting
2
Université M'Hamed Bougara de Boumerdas
Boumerdas, Algeria
Actively Recruiting
3
Flinders University
Adelaide, Australia
Actively Recruiting
4
University of Adelaide
Adelaide, Australia
Actively Recruiting
5
Antwerp University Hospital
Antwerp, Belgium
Actively Recruiting
6
Hospital das Clinicas da Faculdade de Medicina HCFMUSP
São Paulo, Brazil
Actively Recruiting
7
Peking University People's Hospital
Beijing, China
Actively Recruiting
8
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Actively Recruiting
9
Universidad del Rosario - Escuela de Medicina Y Ciencias de La Salud
Bogotá, Colombia
Actively Recruiting
10
Mansoura University, Faculty of Medicine
Al Mansurah, Egypt
Actively Recruiting
11
Al-Azhar University
Cairo, Egypt
Actively Recruiting
12
Cairo University
Cairo, Egypt
Actively Recruiting
13
Universitätsklinikum Schleswig-Holstein
Lübeck, Germany
Actively Recruiting
14
Evangelismos General Hospital
Athens, Greece
Actively Recruiting
15
National and Kapodistrian University of Athens
Athens, Greece
Actively Recruiting
16
National and Kapodistrian University of Athens
Athens, Greece
Actively Recruiting
17
Prabha Eye Clinic & Research Centre
Bangalore, India
Actively Recruiting
18
Postgraduate Institute of Medical Education and Research
Chandigarh, India
Actively Recruiting
19
Shariati Hospital - Tehran University of Medical Sciences
Tehran, Iran
Actively Recruiting
20
Azienda Ospedaliero-Universitaria Senese
Siena, Tuscany, Italy, 53100
Actively Recruiting
21
AOUC Policlinico di Bari
Bari, Italy
Actively Recruiting
22
University of Bari Medical School
Bari, Italy
Actively Recruiting
23
University-Hospital of Bari - UOC Medicina Interna
Bari, Italy
Actively Recruiting
24
University-Hospital of Bari - UOC Pediatria
Bari, Italy
Actively Recruiting
25
University-Hospital of Bari - UOC Reumatologia
Bari, Italy
Actively Recruiting
26
Central Hospital of Bolzano
Bolzano, Italy
Actively Recruiting
27
ASST degli Spedali Civili - P.O. Ospedale dei Bambini
Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network.
Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network.